Perspectives on RNA Interference in Immunopharmacology and Immunotherapy by Hou, Zhaohua et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 14
Perspectives on RNA Interference in
Immunopharmacology and Immunotherapy
Zhaohua Hou, Qiuju Han, Cai Zhang and Jian Zhang
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/61575
Abstract
RNA interference (RNAi), mediated by short interfering RNA (siRNA), vector-derived
short hairpin RNA (shRNA) and microRNA (miRNA), brings about revolutionary fea‐
tures to basic biomedical research and clinical application. New drugs based on RNAi
have been developed for therapeutic applications. The family of RNAi molecules are effi‐
cient agents to modulate mammalian immune system, and many studies reported that
these molecules could manipulate immune defence, surveillance and homeostasis. Both
perfect match of siRNA/shRNA and non-perfect match of miRNA could be beneficial for
designing RNAi-based drugs for treatment of tumour and viral infection. This chapter
provides a view to control or utilize the immune regulation of various small RNAs that
should help researchers to understand the successful clinical application of RNAi.
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1. Introduction
RNA interference (RNAi) is a conserved mechanism against exogenous nucleic acid and
transposon transcripts in plants and lower animals. No matter of transfected siRNA, vector-
delivered shRNA or pre-miRNA (transcribed mainly by Pol II) , Dicer (DCLs) and Agronaute
(AGO) family proteins efficiently process small RNAs into short double-stranded
RNA(dsRNA). Further, dsRNAs assemble into the RNAi-induced silencing (protein) complex
(RISC) to guide and cleave target mRNA, promote mRNA degradation or inhibit mRNA
translation. The great potential of RNAi is to specifically repress the expression of disease-
causing genes while avoiding undesirable effects.
It is well accepted that siRNA can be recognized by endosomal pathways, Toll-like receptor 3
(TLR3), TLR7, TLR8 and cytoplasmic pathways, retinoic acid-inducible gene I (RIG-I),
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melanoma differentiation-associated antigen 5 (MDA-5) and RNA-activated protein kinase
(PKR), resulting in immune activation [1–5]. For example, it has been demonstrated that siRNA
can cause activation of at least three key transcription factors, including NF-κB, interferon
regulatory factor 3 (IRF-3) and IRF-7, and stimulate interferon (IFN) secretion. This activates
T cells and dendritic cells (DCs) in the spleen in a TLR7-dependent manner [2,6]. Furthermore,
5′-triphosphate siRNA was demonstrated to activate RIG-I signal pathway, and then natural
killer (NK) cells and DCs were activated [7,8]. In most circumstances, immune system
stimulation is regarded as an unwanted side effect; therefore, siRNA-induced immune
response should be controlled by using proper delivery system or chemical modification,
although immune stimulation has been proved to be essential in cancer treatment and viral
infection.
miRNAs are critical in regulating the development, differentiation, function and destiny of
immune cells, including DCs, granulocytes, monocytes/macrophages, NK and natural killer
T (NKT) cells and B and T lymphocytes. miRNAs influence both innate and adaptive immune
defence and individual miRNAs may contribute their implications to various immune-
mediated diseases. Furthermore, pattern recognition receptors (PRRs), kinases, adaptors,
inflammatory factors and IFN could all be targets of miRNAs. Extra effort has been made to
develop miRNA-based oligos or vectors for anti-infection purpose by manipulating corre‐
sponding immune genes.
In addition to silencing of targeted genes in a sequence-specific manner, components of RNAi
technology often induce immune response. Several strategies were reported to design RNAi
molecules with gene silencing and immune regulatory properties. Bifunctional molecules rely
on the activation of PRRs such as TLR7/8, TLR9 or RIG-I, or just rely on down-regulation of
target gene. This chapter summarizes RNAi-involved immune responses in the past 10 years
and discusses the anticipated therapeutic application.
2. Chemically synthesized siRNA and vector-derived shRNA
2.1. RNAi drugs based on targeting specific immune genes
Immune disorders, both autoimmune diseases and immune defective or deficiency, are always
caused by high-level overexpression of certain immune genes. A variety of immune inhibitory
genes can serve as targets for RNAi-mediated gene silencing. Targeting specific immune
suppressor could re-balance immune network and subsets.
Elevated activity  of  signal  transducer  and activator  of  transcription 3  (STAT3)  has been
found in several kinds of human tumours. Use of RNAi to knockdown STAT3 expression
and inhibit its activation would reduce the tumour cell growth such as pancreatic cancer,
colorectal cancer, melanoma and hepatocarcinoma cells. STAT 3 knockdown could induce
bystanders immune response in vitro and in vivo, where CD4+, CD8+ and NKT cells were
activated as well as the secretion of interferon-γ (IFN-γ), interleukin-12 (IL-12) and tumour
necrosis factor alpha (TNF-α) was increased significantly [9–11]. siRNA-STAT3, synthetical‐
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ly linked to CpG (agonist of TLR9), was demonstrated to silence immune suppressor STAT3
gene in TLR9+ myeloid cells  and B cells.  This  strategy of  therapy leads to activation of
various  populations  of  immune  cells,  including  DCs  and  macrophages,  that  ultimately
induce potent anti-tumour immune responses [10,12].  Hossain DM et al.  recently report‐
ed that CpG-siRNA-STAT3 conjugates could efficiently silence the target expression, and
abrogate inhibition of CD8+ T cells in patients who received myeloid-derived suppressor
cells (MDSCs) [13]. Researchers proved that immune-stimulation-inducing CpG(A)-STAT3-
siRNA was non-toxic for normal human leukocytes [14]. In another experiment, Luo Z et
al. [15] generated a nano-vaccine loaded with poly I:C (a TLR3 agonist) and STAT3 siRNA.
Researchers found this kind of siRNA could promote the maturation of DC and reverse
immunosuppression in the tumour micro-environment; the function of inhibitory cells in
tumour-draining lymph nodes were inhibited; thus, anti-tumour immune responses were
potently  induced;  and  the  survival  were  prolonged  [15].  Therefore,  STAT3  siRNAs  are
expected to be a promising immunomodulatory drugs to improve the treatment efficacy of
cancer vaccines by abrogating tumour immunosuppression.
Suppressor of cytokine signalling 1 (SOCS1) is a negative regulator of antigen-presenting cell
(APC)-based immune response. Silencing of SOCS1 gene expression by RNAi is essential for
DCs to enhance Ag-specific anti-tumour immunity [16]. SOCS1-silenced bone marrow
dendritic cells (BMDCs) were more potent in suppressing tumour growth [17]. When SOCS1
was silenced, maturation of DCs (i.e. expressions of CD80, CD40, CD86 and major histocom‐
patibility complex II [MHC II]) was significantly accelerated. As a result, SOCS1 inhibition up-
regulated the expression of IFN-γ and IL-12, and decreased IL-4 secretions, which induced
Th1 cell differentiation and thereby affected the development of Th2 cell. The combined
nanoparticle (NP) delivery, which can render both tumour antigen and siRNA-SOCS1 to
BMDCs, simultaneously could enhance immunotherapeutic effects in BMDC-based cancer
therapy [16,18]. DC-targeted delivery of SOCS1 siRNA has been shown to enhance antifungal
immunity in response to Candida albicans in vitro and HIV-specific cytotoxic T cell in mice [16,
19]. This evidence suggests the use of SOCS1–siRNA, as a potent adjuvant to improve immune
response.
A20 is  usually regarded as an attractive target  for  siRNA-mediated gene knockdown in
DCs  because  it  is  a  negative  feedback  regulator  of  multiple  pro-inflammatory  signal
transduction.  Several  reports  demonstrated  that  RNAi-mediated  A20  silencing  in  DCs
enhanced expression of co-stimulatory molecules (CD80, CD86, CD40 and MHC class II)
and pro-inflammatory cytokines (IL-6 and TNF-α). Tumour-infiltrating cytotoxic T lympho‐
cytes (CTLs), T helper cells that produced IL-6 and TNF-α were also activated by siA20-
DC.  A20  silencing  in  DCs  can  enhance  the  immune  response  against  self-tumour-
associated  antigens  [20,21].  Furthermore,  A20-silenced  DCs  were  proved  to  overcome
CD4+CD25+regulatory T (Treg) cell suppression [21,22]. A20-silenced DCs could skew naive
CD4+ T cells towards Th1 cell, but not Treg, Th2 or Th17 cells. Because a high amount of
IL-10 was produced in A20-silenced DCs, simultaneous down-regulation of IL-10 and A20
resulted in enhanced T cell stimulatory capacity in DCs. A20 down-regulation resulted in
enhanced CTLs immune response by the NF-κB and AP-1 pathways [20,23]. RNAi of A20
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has enabled DCs to gain a potent ability to activate CTLs and Th cells, and inhibit Treg,
providing a novel strategy to promote a tumour immune response.
Programmed  death  ligand  (PD-L)  is  another  exciting  target  on  the  surface  of  antigen-
presenting cells (APCs); PD-L/PD-1 interactions were related to functional impairment and
exhaustion of tumour antigen-specific CD8+ T cells. Although PD-L antibody exerts a potent
anti-tumour effect,  previous reports [24] have demonstrated that PD-L1-siRNA-PEI were
preferentially and avidly engulfed by tumour-associated CD11c+PD-L1+ tolerogenic DCs at
ovarian  cancer  locations.  This  kind  of  nanoparticle  uptake  stimulated  multiple  TLRs
signalling,  mainly  via  myeloid  differentiation  factor  88  (MyD88).  Then,  regulatory  DCs
activated into potent stimulators of CTLs that led to significant anti-tumour immunity in
mouse models of ovarian cancer. Most importantly, PD-L knockdown DCs showed superior
potential  to  expand minor histocompatibility antigen (MiHA)-specific  CD8+ effector  and
memory T cells from leukaemia patients early after donor lymphocyte infusion and later
during relapse. Combined PD-L1 and PD-L2 knockdown resulted in improved prolifera‐
tion of CD4+ T cells and enhanced cytokine production [25,26]. In addition, another report
demonstrated the improved effector functions of tumour-specific CD4+ and CD8+ human
T cells by siRNA-mediated silencing of PD-1 ligands, PD-L1 or PD-L2 [27]. These results
suggest  that  siRNA-mediated  knockdown of  PD-L  is  a  fascinating  strategy  to  inhibit  a
negative regulatory mechanism of tumour-specific T cells.
siRNA-CD40, delivered by a novel delivery system with a poly-dA extension at the 5'-end of
the siRNA sense strand that was stably incorporated into 1,3-β-glucan, was captured and
incorporated into DCs through its receptor, Dectin [28]. This strategy could induce antigen-
specific Tregs, resulting in the permanent acceptance of mouse cardiac allografts. CD40
knockdown significantly suppressed Th1-type cytokines and induced Th2-type cytokines in
rats with myocarditis. Knockdown of CD40 in experimental autoimmune myocarditis (EAM)
rats promoted Foxp3 gene expression and increased Treg cells [29].
In addition, when silencing of CD40 or CD80/CD86, DCs exhibited suppressed allostimulatory
activity with impaired APC function. In the well-established collagen-induced arthritis (CIA)
model, multigene-silenced DCs were capable of delaying onset of joint pathology. Therapeutic
effects of gene-silenced DCs were mediated by the inhibition of collagen II-specific Ab
production and suppression of T cell recall responses. Also, multigene-silenced DCs inhibited
Th1 and Th17 response, demonstrating IFN-γ and IL-2 inhibition [30]. Thus, inhibition of
specific co-stimulatory molecules of DCs reveals a promising approach of suppressing
immune responses in autoimmunity. These findings highlight the potential of immunomo‐
dulation of siRNA-CD40, and have important implications for developing RNAi-based clinical
therapy in the transplantation field.
It is well documented that tumours could secrete immunosuppressive molecules, including
the cytokines transforming growth factor β (TGF-β) and IL-10. This creates an immunosup‐
pressive environment, which inhibits anti-tumour immunity. The suppression of Treg cell,
induced by targeting TGF-β1 using siRNA, can enhance the efficacy of a DC vaccine against
a poorly immunogenic tumour in mice [31]. Nanoparticle-delivered TGF-β siRNA enhances
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vaccination against advanced melanoma, and the tumour micro-environment was modified
with increased levels of tumour-infiltrating CD8+ T cells and decreased level of regulatory T
cells [32]. siRNA targeting IL-10 receptor α (siIL-10RA) initiated the significant antigen-specific
CD8+ T cell immune responses. Concordantly, the combination of knockdown of IL-10RA and
TGF-βR in DCs showed significant up-regulation of MHC I, enhancing co-stimulatory
molecules CD40, CD80, CD86 and chemokine CCR7 after lipopolysaccharide (LPS) stimula‐
tion. It induced the strongest anti-tumour effects in the TC-1 P0 (a cervical cancer model
expressing the human papillomavirus [HPV]-16 E7 antigen) tumour model, and even in the
immune-resistant TC-1 (P3) ones [33]. These data revealed that siRNA co-targeting immuno‐
suppressive molecules enhance the potency of DC-based immunotherapeutics.
High-mobility group box 1 (HMGB1) is highly expressed in tumour cells and increased levels
of HMGB1 in tumour cells are usually associated with a greater tumour angiogenesis, growth,
invasion and metastasis. Knockdown of tumour cell-derived HMGB1 by shRNA did not affect
tumour cell growth, while naturally acquired long-lasting tumour-specific IFN-γ- or TNF-α-
producing CD8+ T cell responses were induced, and ability to induce Treg was attenuated.
This led to naturally acquired CD8 T cell-dependent anti-tumour immunity [34].
Foxp3, a master gene that controls the development and function of Treg cells, contributes to
pathogenesis of several different tumours. Owing to the intracellular localization of Foxp3,
RNAi technology was employed to knockdown its activation to suppress Treg activity in vivo.
Tsai et al. [35] performed a study targeting silencing Foxp3 gene expression by shRNAs-
mediated RNAi using a lentivirus vector in a murine model of leukaemia. The lentiviral vector
was used to overcome poor transfection efficiency. Lentiviral-mediated Foxp3 RNAi showed
suppressive effects on tumour growth and prolonged the survival of tumour-transplanted
mice. Furthermore, Foxp3 knockdown mediated by siRNA increased the ratio of Th1/Th2 in
chronic hepatitis B patients; transcription factors T-bet and GATA-3 may be partly involved
in this progress [36]. This strategy provides a novel view about how to decrease the number
of Treg cells and weaken its function.
Selective knockdown of CCL22 and CCL17 expression in monocyte-derived DC (MoDC) by
siRNA decreased the ratios of CD4+ to CD8+ as well as lowered the frequency of Tregs
recruited by MoDC. Furthermore, intratumoural injection of MoDC, which was transfected
with siCCL22 and siCCL17, significantly reduced the number of Tregs while inducing CD8+
T cells infiltration in thymic nude mice with human tumour xenografts [37]. Using siRNA to
selectively silence chemokines may lead to a new strategy for DC vaccine development to
improve cancer biotherapy.
High expression of indoleamine 2, 3-dioxygenase (IDO) in DCs leads to the suppression of T
cell responses. Gene silencing by siRNA or shRNA of IDO in DC would up-regulate IL-12 and
IFN-γ and inhibit apoptosis in CD8 and CD4 T cells as well as Treg cells; IL-10 expression was
significantly down-regulated, thus finally restraining tumour growth. DC-based vaccine with
IDO silence was demonstrated to augment and enhance the anti-tumour response against
breast cancer, melanoma, bladder tumour and liver cancer [38–40]. A novel APC-targeted
siRNA delivery system using mannosed liposomes (Man-lipo) with encapsulated siRNA-IDO
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(Man-lipo-siIDO) was demonstrated to preferentially silence IDO in APCs and efficiently
enhance anti-tumour immune response [41–43].
It was reported that natural killer group 2, member D (NKG2D) activation was involved in
NK cell and CD8+ cell-mediated liver inflammation, and blockade of NKG2D by silencing of
multiple NKG2D ligands on hepatocytes was considered efficient in liver disease intervention.
Huang et al. [44] constructed a plasmid containing the three shRNA sequences (shRae1-
shMult1-shH60). After hydrodynamic injection into mice, they found that the expression of all
three NKG2D ligands on hepatocytes was down-regulated, and fulminant hepatitis mediated
through NKG2D in NK cell was attenuated. Furthermore, simultaneous knockdown of
multiple human NKG2D ligands (MHC class I polypeptide-related sequence B/A(MICA/B),
UL16-binding protein 2 [ULBP2] and ULBP3) also significantly attenuated NK cell cytolysis.
Simultaneous knockdown of multiple ligands of NKG2D is a potential therapeutic approach
to treat liver diseases induced by NKG2D-expressing NK cells and CD8+ cells. Furthermore,
inhibition of human leukocyte antigen-G (HLA-G) by siRNA boosted NK cell lytic function
[45,46].
Among several molecules involved in immune response, the choice of targets should be
carefully reviewed and validated comprehensively according to the emerging knowledge
about their function.
2.2. Advantage of non-target immune effect of siRNA/shRNA drugs
siRNA/shRNA have the potential to recruit immune receptors specialized in RNA sensor, such
as TLR3, TLR7/8 [2,3]. 5′-triphosphate siRNA (3p-siRNA) was demonstrated to be detected by
RNA sensors RIG-I. These immunostimulatory siRNA or shRNA can non-specifically induce
innate immune response, the so-called ‘off-target’ effects that have considerable implications
for clinical application to cure cancer and infection disease.
IFN response is a common side effect of siRNAs and siRNAs with GU-rich sequences, which
are very potent in inducing IFN-α response. A newly published report demonstrated that
siRNA could induce IFN-α responses, and then induced the analgesic effects in the spinal cord.
This off-target analgesia is dose- and sequence-dependent while non-GU-rich sequences also
produced off-target analgesia at high doses, where pain relief by a designed siRNA may not
be attributable to target gene knockdown but IFN response [47].
Early in 2004, Karikó et al. [48] demonstrated that siRNAs and shRNAs induce immune
activation by signalling through TLR3 and activate sequence-independent inhibition of gene
expression. Kleinman et al. [4] showed that non-targeted (against non-mammalian genes) and
targeted (against vascular endothelial growth factor [VEGF] or VEGFR1) siRNAs suppressed
choroidal neovascularization (CNV) via cell-surface TLR3 and its adaptor TIR-domain-
containing adaptor-inducing interferon-β (TRIF), leading to the induction of IFN-α and IL-12.
The effect of non-targeted siRNA to suppress dermal neovascularization in mice was as
effective as vascular endothelial growth factor (VEGF) siRNA. This finding showed that two
investigational siRNAs in clinical trials owe their anti-angiogenic effect in mice, which was
not due to target knockdown but due to TLR3 activation. The efficiency of RNAi by siRNA is
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believed to be comparable with anti-VEGF antibodies. Kleinman’s group then concluded that
a 21-nucleotide (nt) non-targeted siRNA suppresses both hemangiogenesis and lymphangio‐
genesis in mouse models of neovascularization, induced by corneal sutures or hindlimb
ischemia, as efficiently as a 21-nt siRNA targeting VEGF-A [1].
Among 15 siRNAs, Khairuddin et al. [49] identified an extremely immunostimulatory siRNAs,
targeting the HPV, which exerted potent anti-tumoural function. This bifunctional siRNA
could reduce growth of established TC-1 tumours in C57BL/6 mice, and its effect was TLR7
dependent, where ablation of TLR7 recruitment via 2′O-methyl modification of the oligo
backbone reduced these anti-tumour effects. Flatekval et al. [40] designed either monofunc‐
tional siRNAs devoid of immunostimulation or bifunctional siRNAs with IDO silencing and
immunostimulatory activities. They showed that bifunctional siRNAs were able to knock‐
down IDO expression and induce cytokine production through either endosomal TLR7/8 or
RIG-I.
In the past 10 years, several studies reported that bifunctional 3p-siRNA (Exp:targeting Bcl2/
TGF-β/Survivin/Glutaminase/IDO) with target silencing and an innate immunity stimulation
via RIG-I activation could confer potent anti-tumour efficacy. This is illustrated for the first
time by the work of Poeck et al. [8], who reported that bifunctional siRNAs, with 5′-triphos‐
phate targeting Bcl2 (3p-siRNA), led to better melanoma tumour reduction than OH-siRNA
or 5′-triphosphate siRNAs containing target mismatches. Poeck and his colleagues revealed
that siRNA with 5′-triphosphate ends could be recognized by RIG-I and activate an innate
immune cells such as DC; then, expression of IFNs was directly induced, leading to apoptosis
in tumour cells. These bifunctional 3p-siRNAs with RIG-I activation and RNAi-mediated Bcl2
silencing could provoke massive apoptosis of tumour cells in lung metastases in vivo. This
was the first report demonstrating that 3p-siRNA represents a single molecule-based approach
in which RIG-I function activates immune cell and gene silencing, leading to a key molecular
event. Researchers subsequently found that 3p-TGFβ1-siRNA combining RIG-I activation with
gene silencing of TGF-β1 induced profound tumour cell apoptosis and revealed potent anti-
tumour efficacy in pancreatic cancer. This kind of 3p-siRNA induces a Th1 cytokine profile,
demonstrating IFN-γ induction and IL-4 inhibition. High level of IFN and CXCL10 recruited
more activated CD8+ T cells to the tumour. Frequency of immunosuppressive CD11b+ Gr-1+
myeloid cells was reduced after 3p-TGFβ1-siRNA treatment [50].
In addition, 3p-siRNA against survivin gene was designed and generated. This finding
demonstrated that 3p-survivin-siRNA inhibited lung cancer cell proliferation and induced a
RIG-I-dependent type-I interferon response [7]. Recently, 5′-triphosphate siRNA combining
glutaminase (GLS) silencing with RIG-I activation was demonstrated to induce more promi‐
nent anti-tumour responses than RIG-I ligand or GLS silencing capability alone. 3p-siRNA-
GLS effectively induced intrinsic proapoptotic signalling, and GLS silence sensitized
malignant cells to apoptosis induced by RIG-I activation. Moreover, cytotoxicity was en‐
hanced, resulting from disturbed glutaminolysis induced by GLS silencing. Finally, RIG-I
activation by 3p-siRNA-GLS blocked autophagic degradation, leading to dysfunction of
mitochondria, whereas GLS silencing severely impaired reactive oxygen species (ROS)
scavenging systems, leading to a vicious circle of ROS-mediated cytotoxicity [51]. Immature
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monocyte-derived DCs had been transfected with siRNA-bearing 5′-triphosphate-activated T
cells [40].
In addition, 3p-siRNA can inhibit hepatitis B virus (HBV), Influenza A Virus and Coxsackie‐
virus, by gene silencing and RIG-I activation. RNAi provides a promising approach for the
specific treatment of HBV infection. Our laboratory has previously demonstrated that 3p-HBx-
siRNA and shRNA-HBx not only directly inhibit HBV replication but also stimulate innate
immunity against HBV, which are both beneficial for the inversion of HBV-induced immune
tolerance [52]. In HBV-positive hepatoma HepG2.2.15 cells, 3p-HBx-siRNA combining RIG-I
activation with HBx gene silencing induce stronger type I IFN response than non-target 3p-
scramble-siRNA, indicating that a potent immunostimulatory effect may partly contribute to
the reversal of immune tolerance through decreasing HBV load; 3p-HBx-siRNA more strongly
inhibited HBV replication and promoted IFN production than HBx-siRNA in primary HBV(+)
hepatocytes, and this effect was mediated by RIG-I activation [52]. This was consistent of the
other two reports [53,54]. Our dually functional vector containing both an immunostimulatory
single-stranded RNA (ssRNA) and an HBx-silencing shRNA could reverse HBV-induced
hepatocyte-intrinsic immune tolerance; TLR7 signalling pathway was attributed to this
progress [55].
Lin et al. [56] designed and tested a 3p-mNP1496-siRNA against influenza virus. They found
that 3p-mNP1496-siRNA could activate the RIG-I-mediated IFN-β pathway and significantly
reduce virus load and virus-induced pathogenesis. The inhibition effect was in an siRNA- and
RIG-I-dependent manner, demonstrating siRNA playing dual antiviral roles: viral gene-
specific silencing and non-gene-specific RIG-I activation. This strategy was also proved to elicit
potent antiviral effects in coxsackievirus myocarditis, and virus-specific 3p-siRNA was
superior to both conventional virus-specific siRNA and non-target 3p-siRNA in inhibiting viral
replication and subsequent cytotoxicity [57].
In the attempt to inhibit the expression of woodchuck hepatitis virus (WHV), Meng et al. [58]
found that innate immune responses could be enhanced by RNAi through the PKR- and TLR-
dependent signalling pathways in primary hepatocytes. The immunostimulation by RNAi
may contribute to the antiviral activity of siRNAs in vivo.
Furthermore, siRNA can also synergistically enhance DNA-mediated type III IFN (a newly
characterized antiviral interferon) response in non-immune or primary immune cells. This
enhancement is mediated by crosstalk signalling pathway between RIG-I (RNA sensor) and
IFI16 (DNA sensor) [59].
Designing with GU sequences, addition of triphosphate motifs to siRNA, co-treatment with
CpG oligos are believed to activate innate immunity when siRNA was applied in vitro and in
vivo. Accumulating evidence suggests these bifunctional siRNAs could activate NK cells and
CD8+ T cells in different models. Thus, specific clinical applications of RNAi can benefit from
a concurrent activation of the immune system.
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3. miRNA
It has been well discussed how miRNAs regulate signalling pathways, and the dynamics of
the immune response, tolerance and homeostasis. Here we summarize and explore updated
achievements of special miRNAs in immunopharmacology.
3.1. miRNAs as intrinsic targets in antiviral immunity
In addition to the conventional innate and adaptive immune responses, even in the earlier
phase after virus invasion, the host cell suppresses viral replication by evolving the profile of
special and constitutively expressed genes. These cell-intrinsic antiviral approaches based on
host restriction factors may be no less important than in considerations of conventional
immunity. At the same time, viruses also gain some countermeasures or adapt the unique
phenotype of their hosts substantially to survive. Moreover, miRNAs may also be involved in
the inextricably intertwined relationship between viruses and their hosts.
In 2005, a liver-specific miRNA, miR122, which is involved in cholesterol and lipid metabolism
[60], was illustrated to be necessary for hepatitis C virus (HCV) accumulation in cultured liver
cells [61]. Researchers found that miR122 directly binds to two close sites in the 5′ non-coding
region of the HCV genome and promote HCV translation [62–64]. This miRNA kept conserved
among all HCV subtypes [65,66]. Even in non-hepatic cell, miR122 could boost HCV replication
[67]. Moreover, miR122 was further proved to be significantly reduced after IFN-β treatment,
and miR122 mimics neutralized IFN-induced anti-HCV effect [68]. Epidemiological and
genomic researches further suggested that the level of miR122 in individuals with HCV might
be an ’indicator’ for IFN therapy, and only those patients with high levels of miR122 responded
well to IFN therapy [69,70]. Therefore, miR122 antagonist would also be called as IFN ’sensi‐
tizer‘ in HCV immune treatment.
Santaris Pharma designed and synthesized an LNA-based miR122 inhibitor, named Miravirs‐
en (or SPC3649), to eradicate HCV. The product was first evaluated in preclinical studies in
mice [71], cynomolgus monkeys [72], green African monkeys and chimpanzees [73,74]. Here
the key concern is that whether miR122 inhibitor can effectively lower the level of free miR122
and inhibit HCV replication without disturbing normal cholesterol and lipid metabolism or
without any potential chemical toxicity. Interestingly, although there was a reduction of
cholesterol levels in plasma by nearly 40%, Miravirsen caused a dose-dependent reduction of
miR122 and maintained ∼5-week-long half-life in the liver of monkeys and chimpanzees [73,
74]. Moreover, in the high-dose treatment group, Miravirsen decreased HCV subtype 1a or 1b
more than 2 orders of magnitude compared to control group. In all animal species, Miravirsen
was reported to be safe, without serious adverse effects or dose-related toxicities in rats,
monkeys and human [75,76].
In May 2008, Miravirsen was put into human clinical trials as the first miRNA-based drug
(https://clinicaltrials.gov/ct2/show/NCT00979927). There was a significant, dose-dependent
reduction and sustained decrease of HCV viremia after drug administration in human subjects,
and several patients became even HCV undetectable during the study. At the same time, only
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infrequent and moderately adverse effects were caused to some volunteers and did not
influence the trial process [77]. Because miR122 is only liver enriched in physiological condi‐
tions and there is high amount of miR122 in adult human liver, it may be an ideal target to
design highly specific anti-HCV drugs with good resistance to HCV infected person, particu‐
larly to those who have no tolerance to traditional treatments. In the following years, miR196
[78], let-7b family [79] and some other miRNAs were then proved to influence HCV life cycle,
providing new target to restrict hepatitis C infection and avoid chronic infection.
Besides HCV, some other kind of viruses also encode miRNAs or regulate the miRNAs
expression in host cells to disturb the expression of many immune-associated genes directly
and/or indirectly, so that they can be critical regulators for viral life cycle. For example, in
HEK293T cell, prototype foamy virus I (PFV-1) encodes Tas protein to counteract cell-encoded
miR32, which could inhibit PFV-1 gene expression and accumulation [80]. Kaposi’s sarcoma-
associated herpesvirus (KSHV)-induced miR132 could silence p300 expression, which is
critical for the transcription initialization of many antiviral genes, to help themselves maintain
long-time latency [81]. The hematopoietic-cell-specific miR142-3p potently restricts the
replication of eastern equine encephalitis virus in myeloid-lineage cells by binding to the 3′-
untranslated region (UTR) of viral genome [82]. Even Drosha, the enzyme that processes
miRNA biogenesis and maturation, was an independent factor for limiting RNA virus
replication along with canonical type I IFN system in particular cell type [83]. Above of all, it
is much likely that miRNA mimics (for viral inhibitory miRNAs) or antagonists (for viral
beneficial miRNAs) can be effective antiviral strategies as intrinsic immune drugs.
3.2. miRNA regulation antimicrobial and anti-tumour immunity
3.2.1. miRNA in antimicrobial innate immunity
Of the known PRRs, TLRs and RIG-like receptors (RLRs) have been well studied in mediating
antimicrobial and inflammatory responses during infections, which may be targets of patho‐
gens or host-encoded miRNAs.
The first PRR targeting miRNA let7i was reported in 2007 [84], which targeted TLR4 mRNA
in a MyD88/NF-κB-dependent way during Cryptosporidium parvum infection, controlling the
production of inflammatory factors. During Bacillus Calmette-Guérin (BCG) infection, miR124
exerts  its  function  by  targeting  multiple  components  of  the  TLR  signalling  pathway,
including TLR6, MyD88, TNF receptor-associated factor 6 (TRAF6) and TNF-α in mouse
lung cell [85]. After HCV infection, miR373 was induced and negatively regulated the type
I  IFN signalling pathway by suppressing Janus kinase 1(JAK1) and IRF9 in hepatocytes
[86].  Experimental  evaluation using miR124 inhibitors  or  miR373 knockout up-regulated
BCG-induced pro-inflammatory factors  or  type I  IFN and so as  to inhibit  BCG or HCV
more efficiently.  Besides using host  miRNAs,  human cytomegalovirus (HCMV) targeted
TLR2 by encoding its own miRNA, miR-UL112-3p, and reduced the expression of IL-1β,
IL-6 and IL-8 upon stimulation with a TLR2 agonist [87]. Neutralizing this miRNA might
recover normal cytokines production.
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Besides immune inhibitory miRNAs, dengue virus (DENV)-induced miR30e* up-regulated
IFN-β and the downstream IFN-stimulated genes (ISGs) by suppressing IkBα and promoting
NF-κB-dependent IFN production [88]. The transfection of miR30e* would increase the
expression of 2′-5′-oligoadenylate synthetase 1(OAS-1), myxovirus resistance A (MxA) and
interferon-induced transmembrane protein (IFITM). In 2014, miR526 [89] was proved to
enhance RIG-I-induced viral replication by suppression of the expression of cylindromatosis
(CYLD), which suppresses RIG-I K-63-linked polyubiquitin. Moreover, Enterovirus 71(EV71)
inhibited miR526 transcription in an IRF-dependent way and so as to attenuate virus-triggered
type I interferon production. These studies suggested that recruitment or increase of miR30e*
or miR526 would stimulate type I IFN expression and inhibit virus more quickly.
3.2.2. ’Immune miRs‘ as immunopharmaceutic agents
With the general knowledge of immunologically relevant miRNAs established in the past 10
years, many miRNAs have been intensively investigated using gain- and loss-of-function
methods, showing how this novel class of small non-coding RNA participates in mammalian
immunity. And individual immune miRNA might contribute its implications to various
immune-mediated diseases.
The role of miR125b in immune signalling may be paradoxical. After stimulation with LPS,
miR125b was down-regulated and TNF-α, one of miR125b targets, was overexpressed in
RAW264.7, which is essential for antimicrobial activity. Moreover, during M. tuberculosis
infection, the overexpression of miR125a significantly attenuated the antimicrobial effects in
macrophages through targeting UV radiation resistance–associated gene (UVRAG) [90].
Nevertheless, in diffuse large B cell lymphoma (DLBCL), miR125a and miR125b directly target
a negative NF-κB regulator tumour necrosis factor alpha-induced protein 3(TNFAIP3) and
present a positive self-regulatory property to maintain prolonged NF-κB activity. Taken
together, whether overexpression or inhibition of miR125b in an anti-infection therapeutic
study depends on concrete circumstances.
miR146a also acts as a negative regulator in immune sensing. Both in mouse and human,
miR146a was always exploited by virus to attenuate innate and adaptive antiviral immunity
mainly in DC [91], lymphocyte [92] and hepatocytes by inhibiting interleukin-1 receptor-
associated kinase 1(IRAK1), TRAF6 [93], son of sevenless homolog 1 (SOS1) [94] and STAT1
[95]. Silencing of miR146a via the delivery of sponge or antagomiR could restore the expression
of inflammatory factors, augment type I IFN production and promote clearance of vesicular
stomatitis virus (VSV) [96], dengue virus [97], enterovirus 71 (EV71) [94,98] and HBV [95].
Because miR146a was also abnormally expressed in hepatocellular carcinoma (HCC) and
exerted negative anti-tumour effects by up-regulation of immunoinhibitory cytokines such as
TGF-β, IL-17, VEGF, miR146a may also be a novel immunotherapeutic target for HCC [99].
Unlike miR146a, miR155 always promotes immune signal transduction, enhances immune
function or speeds lymphocyte proliferation. Mice lacking miR155 have impaired CTL cell
responses to infections with lymphocytic choriomeningitis virus and the intracellular bacteria
Listeria monocytogenes because of insufficient activation of Akt pathway after TCR cross-linking
[100]. miR155 knockout mice died soon after Erdman (a variant from severe acute respiratory
Perspectives on RNA Interference in Immunopharmacology and Immunotherapy
http://dx.doi.org/10.5772/61575
295
syndrome [SARS]) infection and held higher level of colony-forming units (CFU) in lungs than
wild-type mice [101]. During HIV infection, miR155 inhibited the HIV-activating effects of
tripartite motif-containing protein 32 (TRIM32), and therefore, it might promote a return to
latency in CD4+ reservoir cells [102]. In addition, in NK cells, miR155 might regulate T cell
immunoglobulin-3 (Tim-3)/T-bet/STAT-5-signalling axis, and following cytokine expression
that balanced antiviral response and immune injury during chronic HCV infection [103]. A
remarkably ectopic up-expression of miR155 can be observed by delivering hepatotropic
adeno-associated virus 8 (AAV8) vectors to the liver of mice, and then high level of miR155-
enhanced GAP’s protective capacity against parasite [104]. These studies imply miR155 as an
immune-augmenting adjuvant in improving the antigenicity of vaccination.
miR223 was already proved to be of importance in myeloid progenitor cells proliferation and
responsiveness to pathogenic stimuli in neutrophils by targeting myocyte-specific enhancer
factor 2C (MEF2C), acting as a fine-tune regulator both in normal granulocytes generation and
in preventing aberrant expansion and over-activated inflammatory responses. In recent years,
miR223 was involved in inflammasome response by targeting NLR family pyrin domain
containing 3 (NLRP3) in human [105]. Moreover, Epstein–Barr virus (EBV) encoded a mimic
of hsa-miR223, called miR-BART15, targeting the same site within the NLRP3 3’-UTR to repress
inflammasome activation. Furthermore, this miRNA can be secreted from EBV-infected B cells
into exosomes to rheostat NLRP3 inflammasome activity in non-infected cells [106]. miR223
sponge would balance the amount of NLRP3 and ‘absorb’ EBV-miR-BART15 in macrophages
and DCs.
It is noteworthy that two groups of miRNAs, which shaped NK-mediated cytotoxicity, have
potent value for developing antiviral and anti-tumour biodrugs. First, NKG2D–NKG2D-L
interaction plays a predominant role in ‘NK cell–abnormal cell’ recognition. MICB/A, ULBPs
targeting miRNAs, are not only encoded by human genome as stress regulators but also
synthesized by some virus (e.g. HCMV-miR-UL112 [107], EBV-miRBART2 [108], KSHV-miR-
K12-7 [108] and BK virus (BKV)-miR-B1-3p, JC virus (JCV)-miR-J1-3p[109]), to escape from NK
cell killing. Meanwhile, viral infected cell and tumour cell always express low MICA/B because
of up-regulated MICB/MICA, targeting miRNAs such as miR20a, 93, 103, 106b [110] to
maintain a compromised micro-environment. Furthermore, non-classical human leukocyte
antigen G (HLA-G) is known as an inhibitory ligand, which suppresses the cytotoxic activity
of T and NK cells. Studies demonstrated a strong post-transcriptional gene regulation of the
HLA-G by miR148a, miR148b and miR152, and lower expression of these miRNAs in renal
carcinoma [111] and placental choriocarcinoma cells [112]. Stable manipulation of these
activating and inhibitory miRNAs may enhance NK and LAK cell-mediated cytotoxicity
against infected and tumour cells. Therefore, it could be concluded that modulating the
expression or inhibition of specific miRNAs could boost immune response during viral
infections or against cancers.
3.3. miRNA in maintaining immune homeostasis
Because several miRNAs participate in immune cell development and differentiation,
abnormal expression of miRNA may cause a disturbance of homeostasis by changing the ratio
of helper and regulatory cell subsets, or perturb the functionality and survival of effect-
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memory cells that lead to lymphoproliferative disease. Utilization of miRNA interference
techniques may recover regular immune balance.
3.3.1. miR17-92, miR146a and miR155 in Systemic Lupus Erythematosus (SLE)
In 2007, a unique mouse strain, ‘sanroque’, presented a pattern of lupus pathology, revealing
the core role of T follicular helper (Tfh) in systemic autoimmunity [113]. miR17-92 was found
to regulate Tfh cell differentiation, which is essential for maintenance of the germinal centre
formation and sustained antibody responses. Overexpression of this miRNA in T cells would
enhance Tfh cell proliferation and survive an autoantibody production [112]. Similarly, miR155
increased IL-21-mediated STAT3 signalling in T cell [114], which might accelerate Tfh differ‐
entiation and maturation as well. Moreover, miR155 deficiency ameliorates autoimmune
inflammation of SLE by targeting s1pr1 in mice [115]. Therefore, miR17-92 and miR155 might
be a new target to restrain aggressive autoimmune response in SLE.
3.3.2. miR29 and miR146 in type 1 diabetes
Type 1 diabetes (T1D) is a chronic autoimmune disease that results from the persisting
destruction of pancreatic β-cells by autoreactive CD8+ T cell and Th1 cytokines. Dicer 1 deletion
in β-cell would disrupt normal β-cell development and survival, lead to impairment of insulin
secretion and diabetes development [116], apparently suggesting that miRNAs network is
necessary for normal glycometabolism. Recently, endogenous miR29b released from pancre‐
atic β-cells within exosomes stimulated TNF-α secretion in spleen cells isolated from diabetes-
prone non-obese diabetic (NOD) mice. Delivery of miR29b to mice activated myeloid cell and
pDCs to induce IFN-α, TNF-α and IL-6 production [117]. Abnormal expression of miR146 is
associated with high serum titers of glutamic acid decarboxylase antibody in T1D patients,
indicating the involvement of miR146 in the sustained immune imbalance during T1D
progress [118]. These findings raised the possibility of developing a new clue for T1D immu‐
notherapy using miRNA-based agents.
3.3.3. miR146a and miR155 in rheumatoid arthritis
The role of miR146a in controlling Treg-mediated decrease of Th1 responses has been dem‐
onstrated [119]. In contrast, miR155 promoted Th1 and Th17 differentiation and cell formation
and lowered T cell sensitivity to IFN-γ-driven proliferation by targeting C-MAF and IFNγRα
[120]. Therefore, imbalance of miR146a and miR155 may be an epigenetic phenotype for
autoimmune response. In rheumatoid arthritis (RA), decreased expression of miR146a
contributes to an abnormal Treg phenotype and allows Th1/Th17 skewing while low level of
miR155 failed to support effective Th2 immunity [121]. Systemic administration of miR146a
has potential therapeutic intervention for preventing bone destruction by inhibited Th1 and
Th17 cells, as well as IL-1β, IL-6 and TNF-α [122].
3.3.4. miR15 and miR326 in multiple sclerosis
Multiple sclerosis (MS) is manifested by chronic and progressive inflammatory demyelination
of the central nervous system and is one of the main causes of regressive neurological diseases.
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Study on MS animal model illustrated that mice with fewer Th17 cells were less susceptible to
experimental autoimmune encephalomyelitis (EAE) [123]. Therefore, Th17-targeting biother‐
apeutic approaches may be a promising way to cure multiple sclerosis. Gang Pei’ s laboratory
[124] found that miR326 promoted Th17 differentiation by targeting Ets-1 (a negative regulator
of Th17 polarization) and antagonizing miR326 by sponge vector that resulted in fewer Th17
cells and Th17 cytokines and remitting EAE symptom. Inversely, increased miR155 in primary
human microglia up-regulated pro-inflammatory cytokine secretion and co-stimulatory
surface marker expression suggested that miR155 inhibition in myeloid cell might be useful
to suppress allogeneic T cell responses [125]. In conclusion, reverse pathological expressed
miRNAs and re-balance dysregulated immune genes are of consideration to treat multiple
sclerosis.
4. Conclusion
RNAi technology holds promise for treating various human diseases. It is becoming apparent
that clinical outcome of cancer immunotherapy and infectious diseases can be improved by
targeted strategies to abrogate tumour-induced immunosuppression. Anti-tumour strategies
using siRNA/shRNA/miRNA for both silencing of oncogenes and recruiting of innate recep‐
tors were designed. The present researches highlighted the potential therapeutic applications
of this new generation of siRNAs in immunotherapy.
Additionally, but importantly, siRNA/shRNA or miRNA drugs with regard to pharmacody‐
namic difficulties and unwanted side effects are even more complicated compared to low
molecular weight drugs and hard to be delivered into immune cells. This requires more
extensive procedure than any other traditional drugs. Considering clinical challenges for RNA-
based nucleic acid drugs, including barriers and RNases, the advanced tissue-directed delivery
systems with safety, high efficiency and specificity, long-term function and controllability are
required. Although the exploration of such tiny regulators causally bring pharmacists a
considerable effort to draw up individualized and tailor-made strategies, we believe that
immunoregulation triggered by siRNA/shRNA/miRNA can be used to regulate the host
immunity against cancers or viruses. The development of multifunctional RNAi molecules
will greatly contribute to the future arsenal of tools to combat not only microbial pathogens
but also hard-to-treat cancer.
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